12 Health Care Stocks Moving In Tuesday's After-Market Session

Benzinga · 09/29 21:06
Gainers
- Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million.
- AIxCrypto Hldgs (NASDAQ:AIXC) stock moved upwards by 5.99% to $1.07. The company's market cap stands at $35.0 million.
- Ernexa Therapeutics (NASDAQ:ERNA) shares rose 5.78% to $3.29. The company's market cap stands at $4.0 million.
- Azitra (AMEX:AZTR) stock rose 5.66% to $0.14. The company's market cap stands at $10.2 million.
- Circle8 Group (NASDAQ:CIRC) stock increased by 5.47% to $0.45. The company's market cap stands at $36.5 million.
- Relmada Therapeutics (NASDAQ:RLMD) stock increased by 5.09% to $3.92. The market value of their outstanding shares is at $404.2 million.
Losers
- Stablecoin Development (AMEX:SDEV) shares declined by 24.8% to $2.46 during Tuesday's after-market session. The market value of their outstanding shares is at $42.5 million.
- Accuray (NASDAQ:ARAY) shares decreased by 12.36% to $0.26. The company's market cap stands at $35.8 million.
- Trulieve Cannabis (NYSE:TRLV) stock declined by 8.95% to $11.3. The company's market cap stands at $2.3 billion.
- CytoMed Therapeutics (NASDAQ:GDTC) stock declined by 8.61% to $0.81. The market value of their outstanding shares is at $10.9 million.
- Universe Pharmaceuticals (NASDAQ:UPC) shares decreased by 8.41% to $4.14. The market value of their outstanding shares is at $24.1 million.
- Lantern Pharma (NASDAQ:LTRN) shares decreased by 6.92% to $1.01. The market value of their outstanding shares is at $13.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.